Search For:

  • Use commas to separate words/phrases
    e.g.: gold drill equipment, drilling equipment

Search In:

Search Sectors:

View this profile in: Français
  • 150-700 Collip Cir.
  • N6G4X8
  • P.O. Box 27052
  • N5X3X5

Contact Information

Alternate Telephone:
China, France, Italy, Netherlands, United Kingdom
Number of Employees:
Year Established:
Industries Classification:
334512  Automatic Environmental Control Manufacturing for Residential, Commercial, and Appliance Use
541510  Computer Systems Design and Related Services
541710  Research and Development in the Physical, Engineering and Life Sciences
Total Sales ($CDN):
$1 to $99,999
Updated on:
2015-07-23,  Industry Canada
You must have a valid Industry Canada username and password to modify your company information.
Update Profile

Company Profile

Cytognomix is a London, Ontario based biotechnology company selling software-based solutions and reagents for clinical and research genomics. The company has a significant intellectual property portfolio of patents and copyrights, which emphasizes products for diagnostic applications. Current products include mutation interpretation software, DNA probe reagents for molecular cytogenetics and next generation sequencing. Our breast cancer product line includes hybridization enrichment reagents for breast cancer predisposition, and chemotherapy response. We also have companion software for cytogenetic biodosimetry and to detect chromosome abnormalities at the molecular level.


  • DNA probes for fluorescence in situ hybridization Cytognomix’s proprietary and patented Single Copy (sc) technology brings precise, sensitive, and informative genetic disease management tools to advanced clinical laboratories for detection of chromosome anomalies related to genetic disease. A genome-wide set of custom probes is available for nearly every gene.

  • DNA microarrays Our patented technology is also available for licensing for microarray genomic applications. These products will result in lower coefficients of variation and better quality results for potential licensees. Ultimately, the requirement for reduced amount of content to detect the same abnormalities will simplify regulatory processes and enable more cost effective testing of more patients with few probes.

  • Automated biodosimetry software The company has developed patent pending software to automate and accelerate dicentric chromosome analysis for determining exposures to ionizing radiation. It used for industrial, clinical, or mass casualty exposures to radiation. This is the preferred method has been recommended by the World Health Organization. Our software expedites the analysis by up to 100 fold, removing the major bottleneck in biodosimetry.

  • Mutation interpretation software The identification of disease-causing mutations is the major challenge in personal genome sequencing. We are developing a high throughput software pipeline for distinguishing abnormal DNA sequence changes from common benign genetic variants. This patented product is a collaboration with a major bioinformatics distribution platform with a dedicated customer base of 60,000 researchers and clinicians.

  • Custom DNA capture arrays Based on patented technology, Cytognomix designs and produces solution hybridization capture arrays for unparalleled high density coverage of targeted, effectively unique genomic intervals. The arrays consist of 12,000 oligonucleotide, ~60 mer biotininylated synthetic RNA targets. We work with customers to produce content from genomic sequences beyond the exome.

Back to Top